German Ott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
German Ott has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
A. Rosenwald
Julius-Maximilians-Universität Würzburg
2 shared publicationsAndreas Lohr
From the Pathologisches Institut and Poliklinik für Innere Medizin, University of Würzburg, Germany
1 shared publicationAndreas Rosenwald
From the Pathologisches Institut and Poliklinik für Innere Medizin, University of Würzburg, Germany
1 shared publicationC. Burek
Institut für Pathologie, Julius-Maximilians-Universität Würzburg
1 shared publicationHans Konrad MülLer-Hermelink
From the Pathologisches Institut and Poliklinik für Innere Medizin, University of Würzburg, Germany
1 shared publicationJörG Kalla
From the Pathologisches Institut and Poliklinik für Innere Medizin, University of Würzburg, Germany
1 shared publication
Latest Publications
- 1 February 2007
- Published by Springer Nature in Der Pathologe
- Vol. 28 (1) , 29-35
Sind primär extranodale diffuse großzellige B-Zell-Lymphome organotypische Erkrankungen?
Etwa 30–40% diffuser großzelliger B-Zell-Lymphome (DLBCL) entstehen primär extranodal. Am häufigsten treten sie im Gastrointestinaltrakt auf, überwiegend im Magen, häufiger aber auch in ZNS, Hoden, Lunge oder Haut. Morphologisch zeigen die Tumorzellen das gesamte Spektrum peripherer B-Blasten: Zentroblasten, Immunoblasten oder Plasmoblasten. Von primär nodalen (häufig systemischen) DLBCL sind sie morphologisch also kaum abzugrenzen. Neuere Daten deuten aber darauf hin, dass sich extranodale DLBCL insbesondere in ihren molekularen Charakteristika von nodalen Tumoren (und auch untereinander) unterscheiden und häufig organotypische Eigenschaften aufweisen. Diese betreffen zum einen eine besondere organotypische und/oder klinische Präsentation, wie sie typisch für die in der WHO-Klassifikation definierten Subtypen der DLBCL (primär mediastinales DLBCL, intravaskuläres DLBCL, primäres Ergusslymphom) ist. Zum anderen zeigen primär extranodale DLBCL in der Regel eine gegenüber nodalen Tumoren divergente genetische Konstitution mit besonderen entitätsspezifischen Aberrationen, die wiederum mit dem besonderen Entstehungsort der Tumoren assoziiert scheint, wie z. B. die häufige Deletion des HLA-Genlocus in DLBCL immunprivilegierter Lokalisationen wie ZNS oder Hoden. Schließlich sprechen z. T. sicherlich noch präliminäre Daten für eine besondere organotypische Genexpressionssignatur primär extranodaler DLBCL und damit für offenbar organotypische – unterschiedliche – Transformationswege. Roughly 30–40% of diffuse large B-cell lymphomas (DLBCL) arise primarily in extranodal sites. Most frequently, they occur in the gastrointestinal tract, especially in the gastric mucosa. They also occur in the central nervous system, as testicular lymphomas, in the lungs, or in the skin. Morphologically, they show the whole spectrum of peripheral B-blasts: centroblasts, immunoblasts, or plasmoblasts. Thus, there is no actual difference in their cytomorphological presentation compared to their nodal—and frequently systemic—counterparts. However, recent data point to profound differences in primary extranodal DLBCL compared to primary nodal tumors, as well as to each other, frequently relating to their molecular characteristics and especially implying organotypic features. These characteristics may relate to a particular organotypic site of origin, or the particular clinicopathogenetic setting in which the tumors arise. This is exemplified in the description of the DLBCL subtypes as defined by the World Health Organization classification (mediastinal or intravascular B-cell lymphoma; primary effusion lymphoma). On the other hand, primary extranodal DLBCL are frequently characterized by a particular (cyto-)genetic constitution, often related to their site of origin. Finally, some preliminary data on gene expression profiling strongly argue in favor of particular gene signatures for primary extranodal DLBCL, and hence in favor of particular organotypic transformation pathways.
- 1 February 2007
- Published by Springer Nature in Der Pathologe
- Vol. 28 (1) , 29-35
Sind primär extranodale diffuse großzellige B-Zell-Lymphome organotypische Erkrankungen?
Etwa 30–40% diffuser großzelliger B-Zell-Lymphome (DLBCL) entstehen primär extranodal. Am häufigsten treten sie im Gastrointestinaltrakt auf, überwiegend im Magen, häufiger aber auch in ZNS, Hoden, Lunge oder Haut. Morphologisch zeigen die Tumorzellen das gesamte Spektrum peripherer B-Blasten: Zentroblasten, Immunoblasten oder Plasmoblasten. Von primär nodalen (häufig systemischen) DLBCL sind sie morphologisch also kaum abzugrenzen. Neuere Daten deuten aber darauf hin, dass sich extranodale DLBCL insbesondere in ihren molekularen Charakteristika von nodalen Tumoren (und auch untereinander) unterscheiden und häufig organotypische Eigenschaften aufweisen. Diese betreffen zum einen eine besondere organotypische und/oder klinische Präsentation, wie sie typisch für die in der WHO-Klassifikation definierten Subtypen der DLBCL (primär mediastinales DLBCL, intravaskuläres DLBCL, primäres Ergusslymphom) ist. Zum anderen zeigen primär extranodale DLBCL in der Regel eine gegenüber nodalen Tumoren divergente genetische Konstitution mit besonderen entitätsspezifischen Aberrationen, die wiederum mit dem besonderen Entstehungsort der Tumoren assoziiert scheint, wie z. B. die häufige Deletion des HLA-Genlocus in DLBCL immunprivilegierter Lokalisationen wie ZNS oder Hoden. Schließlich sprechen z. T. sicherlich noch präliminäre Daten für eine besondere organotypische Genexpressionssignatur primär extranodaler DLBCL und damit für offenbar organotypische – unterschiedliche – Transformationswege. Roughly 30–40% of diffuse large B-cell lymphomas (DLBCL) arise primarily in extranodal sites. Most frequently, they occur in the gastrointestinal tract, especially in the gastric mucosa. They also occur in the central nervous system, as testicular lymphomas, in the lungs, or in the skin. Morphologically, they show the whole spectrum of peripheral B-blasts: centroblasts, immunoblasts, or plasmoblasts. Thus, there is no actual difference in their cytomorphological presentation compared to their nodal—and frequently systemic—counterparts. However, recent data point to profound differences in primary extranodal DLBCL compared to primary nodal tumors, as well as to each other, frequently relating to their molecular characteristics and especially implying organotypic features. These characteristics may relate to a particular organotypic site of origin, or the particular clinicopathogenetic setting in which the tumors arise. This is exemplified in the description of the DLBCL subtypes as defined by the World Health Organization classification (mediastinal or intravascular B-cell lymphoma; primary effusion lymphoma). On the other hand, primary extranodal DLBCL are frequently characterized by a particular (cyto-)genetic constitution, often related to their site of origin. Finally, some preliminary data on gene expression profiling strongly argue in favor of particular gene signatures for primary extranodal DLBCL, and hence in favor of particular organotypic transformation pathways.
- 1 July 2006
- Published by Springer Nature in Der Onkologe
- Vol. 12 (7) , 603-611
Maligne Non-Hodgkin-Lymphome der B-Zell-Reihe
- 1 July 2006
- Published by Springer Nature in Der Onkologe
- Vol. 12 (7) , 603-611
Maligne Non-Hodgkin-Lymphome der B-Zell-Reihe
- Open Access
- 15 May 2002
- Published by American Society of Hematology in Blood
- Vol. 99 (10) , 3806-3812
Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3
Follicular lymphoma (FL) grades 1 and 2 are regarded as a distinct disease entity, whereas data suggest that FL grade 3 might be an inhomogeneous tumor category. To define the biologic spectrum of FL, 89 follicular lymphomas were studied for their cytologic composition, antigen expression, mitotic and proliferation indices, cytogenetics, and clinical data. In contrast to the homogeneous appearance of FL grades 1 and 2 (29 and 33 cases, respectively), 2 types of FL grade 3 were recognized. Eleven cases of FL 3a displayed structural features similar to those of FL 1 and 2 and were composed of centroblasts and centrocytes, whereas 16 cases of FL 3b, with (n = 4) or without (n = 12) a diffuse large B-cell lymphoma component (DLBL) (FL 3b ± DLBL), consisted exclusively of blasts. In contrast to FL 3a, FL 3b ± DLBL were CD10+ in only 50% of cases and displayed plasmacytoid differentiation in 44% of cases. Although FL3a was t(14;18)+ in 8 of 11 (73%) cases, only 2 of 16 (13%) FL3b ± DLBLs harbored this translocation. In contrast, chromosomal breaks at 3q27 were encountered in 7 of 16 (44%) FL 3b ± DLBL in contrast to only 2 of 11 (18%) FL 3a, and the spectrum of secondary aberrations in FL 3b ± DLBL was similar to that of diffuse large B-cell lymphoma. We conclude, therefore, that FL grade 3 is a heterogeneous disease group and that the distinction proposed in the new World Health Organization classification between FL 3a (with centrocytes) and FL3b (without centrocytes) is of biologic, and possibly clinical, importance.
- 15 May 2002
- Published by American Society of Hematology in Blood
- Vol. 99 (10) , 3806-3812
Open AccessCytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3
Follicular lymphoma (FL) grades 1 and 2 are regarded as a distinct disease entity, whereas data suggest that FL grade 3 might be an inhomogeneous tumor category. To define the biologic spectrum of FL, 89 follicular lymphomas were studied for their cytologic composition, antigen expression, mitotic and proliferation indices, cytogenetics, and clinical data. In contrast to the homogeneous appearance of FL grades 1 and 2 (29 and 33 cases, respectively), 2 types of FL grade 3 were recognized. Eleven cases of FL 3a displayed structural features similar to those of FL 1 and 2 and were composed of centroblasts and centrocytes, whereas 16 cases of FL 3b, with (n = 4) or without (n = 12) a diffuse large B-cell lymphoma component (DLBL) (FL 3b ± DLBL), consisted exclusively of blasts. In contrast to FL 3a, FL 3b ± DLBL were CD10+ in only 50% of cases and displayed plasmacytoid differentiation in 44% of cases. Although FL3a was t(14;18)+ in 8 of 11 (73%) cases, only 2 of 16 (13%) FL3b ± DLBLs harbored this translocation. In contrast, chromosomal breaks at 3q27 were encountered in 7 of 16 (44%) FL 3b ± DLBL in contrast to only 2 of 11 (18%) FL 3a, and the spectrum of secondary aberrations in FL 3b ± DLBL was similar to that of diffuse large B-cell lymphoma. We conclude, therefore, that FL grade 3 is a heterogeneous disease group and that the distinction proposed in the new World Health Organization classification between FL 3a (with centrocytes) and FL3b (without centrocytes) is of biologic, and possibly clinical, importance.
- 1 May 2002
- Published by Springer Nature in Der Pathologe
- Vol. 23 (3) , 174-176
Molekulare Diagnostik in der Hämatopathologie
Die Diagnostik hämatopoetischer Neoplasien wird heute durch molekular-zytogenetische und molekularbiologische Techniken mehr und mehr verfeinert und ergänzt. Die Grundlage vieler dieser Techniken besteht in der klonalen Natur der (malignen) Tumoren, also in der Tatsache, dass sie sich von einer Zelle oder wenigen Zellen ableiten und somit alle Tochterzellen eine klonale Verwandtschaft aufweisen. Neben dem Klonalitätsnachweis als Marker für eine Neoplasie gewinnen aber auch die Art der primären chromosomalen Aberration und die Zahl bzw. die Art der sekundären, also nach der Tumoretablierung auftretenden, genetischen Veränderungen zunehmend an Bedeutung für die Charakterisierung des biologischen Aggresivitätsgrades. The diagnosis of hematopoietic neoplasias has nowadays become more and more refined by molecular cytogenetic and molecular biological techniques. The biological basis of most of these techniques is that (malignant) tumors represent clonal neoplasias that are derived from a single or few progenitor cells, thus imparting a clonal relationship to all daughter cells. Apart from clonality analysis as a marker for neoplastic growth, the presence or absence of certain primary chromosome abnormalities, and the number and the kind of secondary genetic anomalies become increasingly important in the delineation of the biological grade of aggressiveness.
- 1 May 2002
- Published by Springer Nature in Der Pathologe
- Vol. 23 (3) , 174-176
Molekulare Diagnostik in der Hämatopathologie
Die Diagnostik hämatopoetischer Neoplasien wird heute durch molekular-zytogenetische und molekularbiologische Techniken mehr und mehr verfeinert und ergänzt. Die Grundlage vieler dieser Techniken besteht in der klonalen Natur der (malignen) Tumoren, also in der Tatsache, dass sie sich von einer Zelle oder wenigen Zellen ableiten und somit alle Tochterzellen eine klonale Verwandtschaft aufweisen. Neben dem Klonalitätsnachweis als Marker für eine Neoplasie gewinnen aber auch die Art der primären chromosomalen Aberration und die Zahl bzw. die Art der sekundären, also nach der Tumoretablierung auftretenden, genetischen Veränderungen zunehmend an Bedeutung für die Charakterisierung des biologischen Aggresivitätsgrades. The diagnosis of hematopoietic neoplasias has nowadays become more and more refined by molecular cytogenetic and molecular biological techniques. The biological basis of most of these techniques is that (malignant) tumors represent clonal neoplasias that are derived from a single or few progenitor cells, thus imparting a clonal relationship to all daughter cells. Apart from clonality analysis as a marker for neoplastic growth, the presence or absence of certain primary chromosome abnormalities, and the number and the kind of secondary genetic anomalies become increasingly important in the delineation of the biological grade of aggressiveness.